MONICA BERTAGNOLLI was elected president of the American Society of Clinical Oncology for the term beginning in June 2018.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
